Management ChangeMay 4, 2026, 04:33 PM
Seer Appoints Anthony Bazarko as Chief Commercial Officer
AI Summary
Seer, Inc. announced the appointment of Anthony Bazarko as its new Chief Commercial Officer, effective May 4, 2026. Mr. Bazarko brings over two decades of extensive commercial leadership experience from various life sciences, diagnostics, and biotechnology companies, including Biologos, Specific Diagnostics, Danaher Corporation, and Roche Diagnostics. In his new role, he will lead Seer's Sales, Marketing, and Customer Experience organizations to accelerate the adoption of the Proteograph® Product Suite and drive the company's next phase of growth.
Key Highlights
- Seer appointed Anthony Bazarko as Chief Commercial Officer, effective May 4, 2026.
- Mr. Bazarko brings over two decades of commercial leadership experience in life sciences, diagnostics, and biotechnology.
- He previously served as President and CEO of Biologos from 2022 to 2025, leading its acquisition by Ampersand Capital Partners.
- Prior to Biologos, he was CCO at Specific Diagnostics, developing global go-to-market strategy leading to its acquisition by bioMérieux.
- At Danaher Corporation's Leica Biosystems, he was VP of Commercial Development for the Americas, leading North American strategy, sales, and marketing.
- He also held senior leadership roles at Roche Diagnostics Corporation, overseeing life science tools commercial business and strategic affairs.
- At Seer, Mr. Bazarko will lead Sales, Marketing, and Customer Experience organizations to strengthen commercial execution and drive growth.
Price Impact
More from SEER